DBV Technologies S.A. (DBVT) News & Overview - Discounting Cash Flows
DBVT
DBV Technologies S.A.
DBVT (NASDAQ)

General Overview

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Sector & Industry Healthcare / Biotechnology
Website https://www.dbv-technologies.com
IPO date October 22, 2014

DBVT Latest News

Other Identifiers
CIK0001613780
ISINUS23306J3095
CUSIP23306J101
Open10.15
Previous Close10.49
Volume43.22 Thou.
Average Volume70.67 Thou.
Day’s Range9.5 – 10.53
52 Week Range0.441-12.78
MA (50)9.2892
MA (200)4.73956
Market Cap281.6 Mil.
Shares Out.27.34 Mil.
Earnings DateJul 28, 2025
Beta
Last Dividend
EPS
PE
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us